Added to YB: 2026-01-29
Pitch date: 2026-01-27
SLNO [neutral]
Soleno Therapeutics, Inc.
+23.15%
current return
Author Info
No bio for this author
Company Info
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Market Cap
$2.8B
Pitch Price
$43.03
Price Target
80.00 (+51%)
Dividend
N/A
EV/EBITDA
24.71
P/E
29.97
EV/Sales
8.02
Sector
Biotechnology
Category
growth
$SLNO - Fear, not fluid
SLNO (update): Q3/Q4 revenue miss reveals patients downtitrated below Q2 levels due to Scorpion report psychology, not physiology. Model shows even worst-case titration pause couldn't explain low revenues. Clinical data proves edema affects <3% severely vs current population-wide dosing collapse. Psychology-driven weakness temporary; drug's terminal value intact once fear subsides.
Read full article (5 min)